A Phase 3 interventional study of GSK3511294 (Depemokimab) and Mepolizumab in Asthma, sponsored by GlaxoSmithKline. Completed at 397 sites in 21 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-05-18.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing depemokimab in Asthma — 3 open to participants now, 3 under way, 3 of them phase 3. depemokimab · Asthma.
Among the 10 studies testing depemokimab in Asthma, this one has the largest enrollment, is one of 4 that started in 2021, is one of 7 in phase 3, and was the 2nd registered.
4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.
Browse Asthma studies →3 of the 10 studies testing depemokimab in Asthma are open now, in 12 countries. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States
Ages 6–11
GlaxoSmithKline · Sites in United States, United Kingdom
Ages 12+
GlaxoSmithKline · Sites in United States, Belgium, Canada and 9 more countries
Ages 18+
By country, each count listing its studies:
depemokimab: first FDA approval 2025 (EXDENSUR), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 4 started in 2021.
This study's enrollment of 1,717 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 273 across the 10 interventional studies. Of the 7 that completed or were terminated, 7 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 1 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
262 studies in Asthma by GlaxoSmithKline: 7 open now, 12 under way, 7 of them phase 3. Of 240 finished, 132 (55%) have results posted.
Among the 262 studies in Asthma by GlaxoSmithKline, this one is the 7th largest by enrollment of the 238 interventional ones that give a count, is one of 7 that started in 2021, is one of 61 in phase 3, and was the 236th registered.
GlaxoSmithKline’s Asthma studies by the year they started, since 1999.
1 of the studies testing depemokimab in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07671001Phase 3GlaxoSmithKlineA Study of Depemokimab in Participants of 6 to 11 Years of Age | 2027-03-01 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing depemokimab in Asthma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 262 in Asthma:
This tab as a report to print or save as PDF → With an account.
This study will assess whether switching participants who have benefitted from mepolizumab or benralizumab to GSK3511294 (Depemokimab) is non-inferior to maintaining current treatment on the annualized rate of clinically significant exacerbations in participants with severe asthma with an eosinophilic phenotype. Throughout the study, all participants will continue their non-biologic Baseline standard of care (SoC) asthma treatment.
Key inclusion criteria for study:
Participants receiving either mepolizumab 100 milligrams (mg) or benralizumab 30 mg for >=12 months prior to screening and have a documented benefit to therapy assessed by either:
(i) >=50% reduction in exacerbation frequency since initiating treatment, or (ii) >=50% reduction in maintenance OCS use since initiating treatment, or (iii) No exacerbations in the past 6 months whilst receiving anti-IL-5/5R therapy and an Asthma Control Questionnaire (ACQ)-5 score of less than or equal to (\<=)1.5 at screening.
Key exclusion criteria for study:
Key exclusion criteria for randomization:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received GSK3511294 (Depemokimab) 100 milligrams (mg) subcutaneous (SC) injection administered every 26 weeks (week 0 and week 26) alongside placebo SC treatment matching the active comparator (participant's anti-IL-5/5R treatment prior to randomisation: either placebo matching mepolizumab every 4 weeks or placebo matching benralizumab every 8 weeks).
Biological: GSK3511294 (Depemokimab) · Biological: Placebo · Drug: Standard of care (SoC) · Device: Pre-filled Syringes (PFS)
Participants received their existing active comparator (either mepolizumab 100 mg every 4 weeks or benralizumab 30 mg every 8 weeks) according to the participant's treatment prior to randomisation plus placebo SC matching GSK3511294 (Depemokimab) administered every 26 weeks.
Biological: Mepolizumab · Biological: Benralizumab · Biological: Placebo · Drug: Standard of care (SoC) · Device: Pre-filled Syringes (PFS)
GSK3511294 (Depemokimab) 100 mg SC along with the placebo and SOC will be administered.
Mepolizumab 100 mg SC will be administered in a single-use PFS.
Benralizumab 30 mg will be administered in a single-use PFS.
Placebo will be a sterile liquid formulation.
Non-biologic SoC will include inhaled corticosteroid (ICS) plus at least one other controller, long-acting beta-2-agonist (LABA), long-acting muscarinic antagonist (LAMA), with or without maintenance oral corticosteroids (OCS).
PFS will include glass barrel with pre-staked needle and plunger.
Annualized Rate of Clinically Significant Exacerbations Over 52 Weeks
Clinically significant exacerbations recorded were defined as worsening of asthma requiring the use of systemic corticosteroids (CS) \[such as intramuscular (IM), intravenous (IV) or oral\] and/or hospitalization and/or Emergency Department (ED) visit. For all participants, IV or oral steroids (e.g., prednisone) for at least 3 days or a single IM corticosteroid dose is required. For participants on maintenance systemic corticosteroids, at least double the existing maintenance dose for at least 3 days is required. Exacerbations recorded in the electronic case report form (eCRF) were considered as verified clinically significant exacerbations and included in the primary analysis. Exacerbations separated by less than 7 days was treated as a continuation of the same exacerbation.
Time frame: Up to Week 52
Weighted Mean (WM) Change From Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score
SGRQ: validated, disease specific questionnaire comprising of 51 questions designed to measure health related quality of life in participants with disease of airway obstruction. It assesses how respiratory symptoms and limitations affect daily life. SGRQ 3 domains: Symptoms, Activity and, Impacts. Each item has an empirically derived weight, and domain scores are combined to produce a total score ranging: 0 to 100. Scores are expressed as a percentage of overall impairment between 100 (worst possible health status) and 0 (best possible health status). Higher scores indicating greater impairment of quality of life. Change from Baseline (CFB): value at indicated time point minus Baseline value. For each participant, WM CFB in SGRQ total score was calculated using linear trapezoidal rule to estimate area under the curve (AUC) from Baseline (Day 1) across Weeks 4, 12, 26, and 52 and presented as a single consolidated SGRQ total score on original scale (i.e., not expressed per unit time).
Time frame: From Baseline (Day 1) up to Week 52
Weighted Mean Change From Baseline in Asthma Control Questionnaire-5 (ACQ-5) Score
The ACQ 5 is a validated, 5-item patient reported tool assessing asthma symptoms over the past week. The 5 questions enquired to recall how their asthma had been during the previous week and to respond about the frequency and/or severity of symptoms (nocturnal awakening, waking in the morning, activity limitation, shortness of breath and wheezing). Each item is scored from 0 (no impairment) to 6 (maximum impairment), and the final ACQ 5 score is the average of all items, ranging from 0 to 6. Lower scores indicate better asthma control, while higher scores indicate poorer control. CFB was defined as value at the indicated time point minus Baseline value. For each participant, the WM CFB in ACQ-5 score was calculated using the linear trapezoidal rule to estimate the AUC from Baseline (Day 1) across Weeks 4, 8, 12, 16, 20, 24, 26, 28, 32, 36, 40, 44, 48 and 52) and presented as a single consolidated ACQ-5 score on the original scale (i.e., not expressed per unit/time).
Time frame: From Baseline (Day 1) up to Week 52
Weighted Mean Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1)
Forced Expiratory Volume in One Second (FEV1) is defined as the volume of air that can be forced out in one second after taking a deep breath by a person and was measured by spirometry testing. Change from Baseline in clinic pre-bronchodilator FEV1 was determined. Change from Baseline was defined as value at the indicated time point minus Baseline value. For each participant, the WM change from baseline in FEV1 was calculated using the linear trapezoidal rule to estimate the AUC from Baseline (Day 1) across Weeks 12, 26, 40, and 52). WM change from baseline in FEV1 over 52-week period was presented as a single consolidated data.
Time frame: From Baseline (Day 1) up to Week 52
A total of 1717 participants were randomized to the study out of which 1687 participants were included in Full Analysis Set (FAS). FAS population included all randomised participants who received at least one dose of study intervention excluding 27 participants from 4 sites with Good Clinical Practices (GCP) non-compliance/significant data integrity concerns and 3 were randomized in error but did not receive study intervention.
| Milestone | Depemokimab 100mg SC | Mepolizumab 100 mg / Benralizumab 30 mg SC |
|---|---|---|
| Started | 859 | 858 |
| Fas | 848 | 839 |
| Safety-modified set | 859 | 855 |
| Completed | 763 | 772 |
| Not completed | 96 | 86 |
| Withdrew: Adverse event | 7 | 1 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Lack of efficacy | 12 | 6 |
| Withdrew: Lost to follow-up | 16 | 7 |
| Withdrew: Protocol violation | 8 | 3 |
| Withdrew: Physician decision | 2 | 5 |
| Withdrew: Withdrawal by subject | 37 | 44 |
| Withdrew: Subject reached protocol defined stopping criteria | 3 | 0 |
| Withdrew: Gcp violation sites | 11 | 16 |
| Withdrew: No study intervention received | 0 | 3 |
Clinically significant exacerbations recorded were defined as worsening of asthma requiring the use of systemic corticosteroids (CS) \[such as intramuscular (IM), intravenous (IV) or oral\] and/or hospitalization and/or Emergency Department (ED) visit. For all participants, IV or oral steroids (e.g., prednisone) for at least 3 days or a single IM corticosteroid dose is required. For participants on maintenance systemic corticosteroids, at least double the existing maintenance dose for at least 3 days is required. Exacerbations recorded in the electronic case report form (eCRF) were considered as verified clinically significant exacerbations and included in the primary analysis. Exacerbations separated by less than 7 days was treated as a continuation of the same exacerbation.
| Exacerbation per participant per year | Depemokimab 100mg SC | Mepolizumab 100 mg / Benralizumab 30 mg SC |
|---|---|---|
| Annualized Rate of Clinically Significant Exacerbations Over 52 Weeks | 0.57 (0.50 to 0.64) | 0.49 (0.43 to 0.55) |
SGRQ: validated, disease specific questionnaire comprising of 51 questions designed to measure health related quality of life in participants with disease of airway obstruction. It assesses how respiratory symptoms and limitations affect daily life. SGRQ 3 domains: Symptoms, Activity and, Impacts. Each item has an empirically derived weight, and domain scores are combined to produce a total score ranging: 0 to 100. Scores are expressed as a percentage of overall impairment between 100 (worst possible health status) and 0 (best possible health status). Higher scores indicating greater impairment of quality of life. Change from Baseline (CFB): value at indicated time point minus Baseline value. For each participant, WM CFB in SGRQ total score was calculated using linear trapezoidal rule to estimate area under the curve (AUC) from Baseline (Day 1) across Weeks 4, 12, 26, and 52 and presented as a single consolidated SGRQ total score on original scale (i.e., not expressed per unit time).
| Scores on Scale | Depemokimab 100mg SC | Mepolizumab 100 mg / Benralizumab 30 mg SC |
|---|---|---|
| Weighted Mean (WM) Change From Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score | -0.69 ± 0.476 | -0.86 ± 0.486 |
The ACQ 5 is a validated, 5-item patient reported tool assessing asthma symptoms over the past week. The 5 questions enquired to recall how their asthma had been during the previous week and to respond about the frequency and/or severity of symptoms (nocturnal awakening, waking in the morning, activity limitation, shortness of breath and wheezing). Each item is scored from 0 (no impairment) to 6 (maximum impairment), and the final ACQ 5 score is the average of all items, ranging from 0 to 6. Lower scores indicate better asthma control, while higher scores indicate poorer control. CFB was defined as value at the indicated time point minus Baseline value. For each participant, the WM CFB in ACQ-5 score was calculated using the linear trapezoidal rule to estimate the AUC from Baseline (Day 1) across Weeks 4, 8, 12, 16, 20, 24, 26, 28, 32, 36, 40, 44, 48 and 52) and presented as a single consolidated ACQ-5 score on the original scale (i.e., not expressed per unit/time).
| Scores on Scale | Depemokimab 100mg SC | Mepolizumab 100 mg / Benralizumab 30 mg SC |
|---|---|---|
| Weighted Mean Change From Baseline in Asthma Control Questionnaire-5 (ACQ-5) Score | 0.03 ± 0.026 | 0.06 ± 0.026 |
Forced Expiratory Volume in One Second (FEV1) is defined as the volume of air that can be forced out in one second after taking a deep breath by a person and was measured by spirometry testing. Change from Baseline in clinic pre-bronchodilator FEV1 was determined. Change from Baseline was defined as value at the indicated time point minus Baseline value. For each participant, the WM change from baseline in FEV1 was calculated using the linear trapezoidal rule to estimate the AUC from Baseline (Day 1) across Weeks 12, 26, 40, and 52). WM change from baseline in FEV1 over 52-week period was presented as a single consolidated data.
| Liter | Depemokimab 100mg SC | Mepolizumab 100 mg / Benralizumab 30 mg SC |
|---|---|---|
| Weighted Mean Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) | -0.014 ± 0.0093 | -0.018 ± 0.0095 |
Collected over All cause mortality, SAEs and other AEs were collected from signing of Informed Consent (Day -1) up to week 56 (End of follow up).. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Depemokimab 100mg SC | 0/859 (0%) | 81/859 (9.4%) | 587/859 (68.3%) |
| Mepolizumab 100 mg / Benralizumab 30 mg SC | 1/855 (0.1%) | 76/855 (8.9%) | 554/855 (64.8%) |
| Event | Depemokimab 100mg SC | Mepolizumab 100 mg / Benralizumab 30 mg SC |
|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 19/859 | 12/855 |
| PneumoniaInfections and infestations | 11/859 | 7/855 |
| COVID-19Infections and infestations | 7/859 | 4/855 |
| Urinary tract infectionInfections and infestations | 0/859 | 3/855 |
| InfluenzaInfections and infestations | 3/859 | 0/855 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 3/859 | 1/855 |
| Atrial fibrillationCardiac disorders | 1/859 | 2/855 |
| Infective exacerbation of asthmaInfections and infestations | 0/859 | 2/855 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 2/859 | 2/855 |
| Acute myocardial infarctionCardiac disorders | 2/859 | 1/855 |
| Event | Depemokimab 100mg SC | Mepolizumab 100 mg / Benralizumab 30 mg SC |
|---|---|---|
| NasopharyngitisInfections and infestations | 177/859 | 171/855 |
| COVID-19Infections and infestations | 157/859 | 143/855 |
| Upper respiratory tract infectionInfections and infestations | 98/859 | 111/855 |
| CoughRespiratory, thoracic and mediastinal disorders | 67/859 | 42/855 |
| HeadacheNervous system disorders | 58/859 | 62/855 |
| SinusitisInfections and infestations | 57/859 | 50/855 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 37/859 | 53/855 |
| InfluenzaInfections and infestations | 50/859 | 38/855 |
| Respiratory tract infectionInfections and infestations | 47/859 | 39/855 |
| BronchitisInfections and infestations | 43/859 | 31/855 |
FAS was defined as all randomised participants who received at least one dose of study intervention excluding participants from sites with GCP non-compliance/significant data integrity concerns.
| Age, Continuous(YEARS) | Depemokimab 100mg SC | Mepolizumab 100 mg / Benralizumab 30 mg SC | Total |
|---|---|---|---|
| Mean | 58.3 ± 13.24 | 58.9 ± 13.24 | 58.6 ± 13.24 |
| Sex: Female, Male(Participants) | Depemokimab 100mg SC | Mepolizumab 100 mg / Benralizumab 30 mg SC | Total |
|---|---|---|---|
| Female | 528 | 522 | 1050 |
| Male | 320 | 317 | 637 |
| Race/Ethnicity, Customized(Participants) | Depemokimab 100mg SC | Mepolizumab 100 mg / Benralizumab 30 mg SC | Total |
|---|---|---|---|
| AMERICAN INDIAN OR ALASKA NATIVE | 3 | 3 | 6 |
| ASIAN | 148 | 140 | 288 |
| BLACK OR AFRICAN AMERICAN | 26 | 35 | 61 |
| NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER | 2 | 4 | 6 |
| WHITE | 659 | 645 | 1304 |
| MIXED RACE | 5 | 5 | 10 |
| Other: Unspecified | 5 | 7 | 12 |
Showing the first 100 of 397 sites across 21 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Jan 2021 to primary completion in Sep 2025, 55 months.
Results were first posted in May 2026, 8 months after primary completion.
Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 55 months is above that.
Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Depemokimab